English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 62.00%
Price change 2019 → 2020: 179.01%
Price change 2020 → 2021: -31.86%
Price change 2021 → 2022: -77.14%
Price change 2022 → 2023: 2.13%
Price change 2023 → 2024: -14.05%
Price change 2024 → 2025: -17.80%
Price change 2025 → 2026: 35.04%
Price change 2026 (year to date): 26.57%
Financial growth
Revenue CAGR (8 years): 190.08%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.17
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -50.00
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 22.05% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ALNLF.PA" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Neolife S.A. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 8.8 m | -577,392 | -6.6 % | n/a |
| 2021 | 12.0 m | -340,041 | -2.8 % | +36.9 % |
| 2022 | 14.9 m | -4.1 m | -27.2 % | +24.2 % |
| 2023 | 15.0 m | -585,501 | -3.9 % | +0.8 % |
| 2024 | 13.6 m | 528,994 | 3.9 % | -9.4 % |
| 2025 | 13.9 m | -130,851 | -0.9 % | +2.2 % |
Amounts converted to USD. Source: published annual accounts, collected on 30/10/2026.
Accounts and financial health
Balance sheet and cash flow published by Neolife S.A. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 1.8 m | 1.4 m | 1.0 m | 1.9 m | 1.3 m |
| Total Debt | 2.7 m | 2.0 m | 1.5 m | 911,055 | 749,258 |
| Net Debt | 871,799 | 657,664 | 552,566 | -822,577 | -294,125 |
| Equity | 2.2 m | 4.8 m | 4.3 m | 4.9 m | 4.5 m |
| Total assets | 8.4 m | 8.3 m | 7.3 m | 8.8 m | 9.5 m |
| Operating cash flow | -94,408 | -860,840 | 653 | 1,880 | 612,000 |
| Investments (capex) | 844,802 | 363,912 | 0 | 0 | 0 |
| Free cash-flow | -939,210 | -1.2 m | 653 | 1,880 | 612,000 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in EUR, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 02/11/2026.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Neolife S.A.
What is the Neolife S.A. share price?
Latest recorded price: 0.0582 EUR on 30/10/2026, for a market cap of 6.3 m USD.
What is the revenue of Neolife S.A.?
13.9 m USD for fiscal year 2025, with net income of -130,851 USD (net margin -0.9 %).
Is Neolife S.A. stock eligible for the French PEA?
Likely: the company is headquartered in the European Union or the European Economic Area (ISIN FR0011636083) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.
How many employees does Neolife S.A. have?
18 full-time employees according to the latest published profile.
Who runs Neolife S.A.?
Marie Berland is the company's chief executive.